{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:50:14Z","timestamp":1791298214529,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40263-017-0449-5","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T06:33:05Z","timestamp":1498890785000},"page":"665-674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder"],"prefix":"10.1007","volume":"31","author":[{"given":"Andrew","family":"Naglich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-2642","authenticated-orcid":false,"given":"Bryon","family":"Adinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-3743","authenticated-orcid":false,"given":"E. Sherwood","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"449_CR1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jpsychires.2016.10.003","volume":"84","author":"C Blanco","year":"2017","unstructured":"Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions\u2014III. J Psychiatr Res. 2017;84:310\u20137.","journal-title":"J Psychiatr Res"},{"key":"449_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YCO.0b013e32834de3de","volume":"25","author":"KR Merikangas","year":"2012","unstructured":"Merikangas KR, Lamers F. The, \u201ctrue\u201d prevalence of bipolar II disorder. Curr Opin Psychiatry. 2012;25:19\u201323.","journal-title":"Curr Opin Psychiatry."},{"key":"449_CR3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/00023210-200721090-00003","volume":"21","author":"F Benazzi","year":"2007","unstructured":"Benazzi F. Bipolar II disorder. CNS Drugs. 2007;21:727\u201340.","journal-title":"CNS Drugs"},{"key":"449_CR4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72:757.","journal-title":"JAMA Psychiatry."},{"key":"449_CR5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00005053-192104000-00057","volume":"53","author":"E Kraepelin","year":"1921","unstructured":"Kraepelin E. Manic depressive insanity and paranoia. J Nerv Ment Dis. 1921;53:350.","journal-title":"J Nerv Ment Dis."},{"key":"449_CR6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eurpsy.2013.07.004","volume":"29","author":"A Florio Di","year":"2014","unstructured":"Di Florio A, Craddock N, van denBree M. Alcoholmisuse in bipolardisorder. A systematic review and meta-analysis of comorbidity rates. Eur Psychiatry. 2014;29:117\u201324.","journal-title":"Eur Psychiatry."},{"key":"449_CR7","doi-asserted-by":"publisher","unstructured":"Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry. 2010;12(5). doi: 10.4088\/PCC.09m00883yel . (pii: PCC.09m00883).","DOI":"10.4088\/PCC.09m00883yel"},{"key":"449_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2013.01.036","volume":"149","author":"E Leclerc","year":"2013","unstructured":"Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013;149:247\u201352.","journal-title":"J Affect Disord"},{"key":"449_CR9","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1017\/S0033291713000329","volume":"43","author":"C Clements","year":"2013","unstructured":"Clements C, Morriss R, Jones S, et al. Suicide in bipolar disorder in a national English sample, 1996\u20132009: frequency, trends and characteristics. Psychol Med. 2013;43:2593\u2013602.","journal-title":"Psychol Med"},{"key":"449_CR10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.4088\/JCP.13m08899","volume":"75","author":"RT Webb","year":"2014","unstructured":"Webb RT, Lichtenstein P, Larsson H, et al. Suicide, hospital-presenting suicide attempts, and criminality in bipolar disorder: examination of risk for multiple adverse outcomes. J Clin Psychiatry. 2014;75:809\u201316.","journal-title":"J Clin Psychiatry"},{"key":"449_CR11","doi-asserted-by":"crossref","first-page":"902","DOI":"10.4088\/JCP.09m05198gry","volume":"71","author":"MA Oquendo","year":"2010","unstructured":"Oquendo MA, Currier D, Liu S-M, et al. Increased risk for suicidal behavior in comorbid bipolar disorder and alcohol use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2010;71:902\u20139.","journal-title":"J Clin Psychiatry"},{"key":"449_CR12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euroneuro.2006.10.002","volume":"17","author":"P Najt","year":"2007","unstructured":"Najt P, Perez J, Sanches M, et al. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol. 2007;17:313\u201320.","journal-title":"Eur Neuropsychopharmacol"},{"key":"449_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0165-0327(95)00080-1","volume":"37","author":"JA Feinman","year":"1996","unstructured":"Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affect Disord. 1996;37:43\u20139.","journal-title":"J Affect Disord"},{"key":"449_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.psy.0000151489.36347.18","volume":"67","author":"KRR Krishnan","year":"2005","unstructured":"Krishnan KRR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005;67:1\u20138.","journal-title":"Psychosom Med"},{"key":"449_CR15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4088\/JCP.v67n0609","volume":"67","author":"BI Goldstein","year":"2006","unstructured":"Goldstein BI, Levitt AJ. A gender-focused perspective on health service utilization in comorbid bipolar I disorder and alcohol use disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2006;67:925\u201332.","journal-title":"J Clin Psychiatry"},{"key":"449_CR16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11920-012-0320-9","volume":"14","author":"CK Farren","year":"2012","unstructured":"Farren CK, Hill KP, Weiss RD. Bipolar disorder and alcohol use disorder: a review. Curr Psychiatry Rep. 2012;14:659\u201366.","journal-title":"Curr Psychiatry Rep."},{"key":"449_CR17","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.jcp.0000138763.23482.2a","volume":"24","author":"EP Monnelly","year":"2004","unstructured":"Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:532\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"449_CR18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/01.jcp.0000106230.36344.b1","volume":"24","author":"J Longoria","year":"2004","unstructured":"Longoria J, Brown ES, Perantie DC, et al. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol. 2004;24:101\u20132.","journal-title":"J Clin Psychopharmacol"},{"key":"449_CR19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hup.944","volume":"23","author":"G Martinotti","year":"2008","unstructured":"Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol Clin Exp. 2008;23:417\u201324.","journal-title":"Hum Psychopharmacol Clin Exp."},{"key":"449_CR20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4088\/JCP.v69n0502","volume":"69","author":"ES Brown","year":"2008","unstructured":"Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2008;69:701\u20135.","journal-title":"J Clin Psychiatry"},{"key":"449_CR21","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1530-0277.2010.01270.x","volume":"34","author":"M Stedman","year":"2010","unstructured":"Stedman M, Pettinati HM, Brown ES, et al. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar i patients with coexisting alcohol dependence. Alcohol Clin Exp Res. 2010;34:1822\u201331.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR22","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/acer.12445","volume":"38","author":"ES Brown","year":"2014","unstructured":"Brown ES, Davila D, Nakamura A, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res. 2014;38:2113\u20138.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","volume":"66","author":"ES Brown","year":"2005","unstructured":"Brown ES, Jeffress J, Liggin JDM, et al. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66:756\u201360.","journal-title":"J Clin Psychiatry"},{"key":"449_CR24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-5618.2006.00292.x","volume":"8","author":"G Rubio","year":"2006","unstructured":"Rubio G, L\u00f3pez-Mu\u00f1oz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8:289\u201393.","journal-title":"Bipolar Disord"},{"key":"449_CR25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.62.1.37","volume":"62","author":"IM Salloum","year":"2005","unstructured":"Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37\u201345.","journal-title":"Arch Gen Psychiatry"},{"key":"449_CR26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0376-8716(02)00105-9","volume":"67","author":"KT Brady","year":"2002","unstructured":"Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67:323\u201330.","journal-title":"Drug Alcohol Depend"},{"key":"449_CR27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004583-199802000-00009","volume":"37","author":"B Geller","year":"1998","unstructured":"Geller B, Cooper TB, Sun K, et al. Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry. 1998;37:171\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"449_CR28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/da.20213","volume":"23","author":"ES Brown","year":"2006","unstructured":"Brown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006;23:492\u20135.","journal-title":"Depress Anxiety."},{"key":"449_CR29","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","volume":"33","author":"ES Brown","year":"2009","unstructured":"Brown ES, Carmody TJ, Schmitz JM, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33:1863\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR30","doi-asserted-by":"crossref","first-page":"12983","DOI":"10.3390\/ijerph111212983","volume":"11","author":"A Icro Maremmani","year":"2014","unstructured":"Icro Maremmani A, Bacciardi S, Rovai L, et al. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health. 2014;11:12983\u201396.","journal-title":"Int J Environ Res Public Health."},{"key":"449_CR31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/ADT.0b013e31816719df","volume":"8","author":"BK Tolliver","year":"2009","unstructured":"Tolliver BK, McRae AL, Sonne SC, Brady KT. Safety and tolerability of acamprosate in alcohol-dependent individuals with bipolar disorder: an open-label pilot study. Addict Disord Their Treat. 2009;8:33\u20138.","journal-title":"Addict Disord Their Treat."},{"key":"449_CR32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1399-5618.2011.00973.x","volume":"14","author":"BK Tolliver","year":"2012","unstructured":"Tolliver BK, DeSantis SM, Brown DG, et al. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report: alcohol dependence and bipolar disorder. Bipolar Disord. 2012;14:54\u201363.","journal-title":"Bipolar Disord"},{"key":"449_CR33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","volume":"57","author":"IL Petrakis","year":"2005","unstructured":"Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57:1128\u201337.","journal-title":"Biol Psychiatry"},{"key":"449_CR34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/ajad.12346","volume":"25","author":"LG Sylvia","year":"2016","unstructured":"Sylvia LG, Gold AK, Stange JP, et al. A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder: efficacy of topiramate. Am J Addict. 2016;25:94\u20138.","journal-title":"Am J Addict."},{"key":"449_CR35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/00952990.2015.1114118","volume":"42","author":"H Xiao","year":"2016","unstructured":"Xiao H, Wignall N, Brown ES. An open-label pilot study of icariin for co-morbid bipolar and alcohol use disorder. Am J Drug Alcohol Abuse. 2016;42:162\u20137.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"449_CR36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lfs.2015.01.006","volume":"126","author":"C Li","year":"2015","unstructured":"Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci. 2015;126:57\u201368.","journal-title":"Life Sci"},{"key":"449_CR37","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.4088\/JCP.12r08178","volume":"74","author":"T Kishi","year":"2013","unstructured":"Kishi T, Sevy S, Chekuri R, Correll CU. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 2013;74:e642\u201354.","journal-title":"J Clin Psychiatry"},{"key":"449_CR38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","volume":"36","author":"RZ Litten","year":"2012","unstructured":"Litten RZ, Fertig JB, Falk DE, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res. 2012;36:406\u201316.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.addbeh.2010.11.006","volume":"36","author":"J Guardia","year":"2011","unstructured":"Guardia J, Roncero C, Galan J, et al. A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients. Addict Behav. 2011;36:265\u20139.","journal-title":"Addict Behav"},{"key":"449_CR40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/jcp.0b013e3181602fd4","volume":"28","author":"RF Anton","year":"2008","unstructured":"Anton RF, Kranzler H, Breder C, et al. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28:5\u201312.","journal-title":"J Clin Psychopharmacol"},{"key":"449_CR41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s002130000629","volume":"155","author":"KE Hutchison","year":"2001","unstructured":"Hutchison KE, Swift R, Rohsenow DJ, et al. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology. 2001;155:27\u201334.","journal-title":"Psychopharmacology"},{"key":"449_CR42","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/sj.npp.1300917","volume":"31","author":"KE Hutchison","year":"2006","unstructured":"Hutchison KE, Ray L, Sandman E, et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacol. 2006;31:1310\u20137.","journal-title":"Neuropsychopharmacol."},{"key":"449_CR43","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00213-014-3757-1","volume":"232","author":"RA Littlewood","year":"2015","unstructured":"Littlewood RA, Claus ED, Arenella P, et al. Dose specific effects of olanzapine in the treatment of alcohol dependence. Psychopharmacology. 2015;232:1261\u20138.","journal-title":"Psychopharmacology"},{"key":"449_CR44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.ALC.0000125352.06688.F7","volume":"28","author":"J Guardia","year":"2004","unstructured":"Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28:736\u201345.","journal-title":"Alcohol Clin Exp Res"},{"key":"449_CR45","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","volume":"26","author":"AR Lingford-Hughes","year":"2012","unstructured":"Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol (Oxf). 2012;26:899\u2013952.","journal-title":"J Psychopharmacol (Oxf)."},{"key":"449_CR46","doi-asserted-by":"crossref","unstructured":"Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxf). 2016;30:495\u2013553.","DOI":"10.1177\/0269881116636545"},{"issue":"2","key":"449_CR47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/15622975.2016.1246752","volume":"18","author":"M Soyka","year":"2017","unstructured":"Soyka M, Kranzler HR, Hesselbrock V, et al. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2017;18(2):86-119.","journal-title":"World J Biol Psychiatry."},{"key":"449_CR48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00000441-197407000-00002","volume":"268","author":"NS Kline","year":"1974","unstructured":"Kline NS, Wren JC, Cooper TB, et al. Evaluation of lithium therapy in chronic and periodic alcoholism. Am J Med Sci. 1974;268:15\u201322.","journal-title":"Am J Med Sci"},{"key":"449_CR49","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(76)90784-4","volume":"308","author":"J Merry","year":"1976","unstructured":"Merry J, Reynolds C, Bailey J, Coppen A. Prophylactic treatment of alcoholism by lithium carbonate: a controlled study. Lancet. 1976;308:481\u20132.","journal-title":"Lancet"},{"key":"449_CR50","first-page":"494","volume":"45","author":"J Fawcett","year":"1984","unstructured":"Fawcett J, Clark DC, Gibbons RD, et al. Evaluation of lithium therapy for alcoholism. J Clin Psychiatry. 1984;45:494\u20139.","journal-title":"J Clin Psychiatry"},{"key":"449_CR51","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/archpsyc.1987.01800150060008","volume":"44","author":"J Fawcett","year":"1987","unstructured":"Fawcett J, Clark DC, Aagesen CA, et al. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987;44:248\u201356.","journal-title":"Arch Gen Psychiatry"},{"key":"449_CR52","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1001\/jama.1989.03430120100029","volume":"262","author":"W Dorus","year":"1989","unstructured":"Dorus W, Ostrow DG, Anton R, et al. Lithium treatment of depressed and nondepressed alcoholics. JAMA. 1989;262:1646\u201352.","journal-title":"JAMA"},{"key":"449_CR53","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jad.2012.07.005","volume":"144","author":"B Etain","year":"2013","unstructured":"Etain B, Mathieu F, Liquet S, et al. Clinical features associated with trait-impulsiveness in euthymic bipolar disorder patients. J Affect Disord. 2013;144:240\u20137.","journal-title":"J Affect Disord"},{"key":"449_CR54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1399-5618.2009.00678.x","volume":"11","author":"AC Swann","year":"2009","unstructured":"Swann AC, Lijffijt M, Lane SD, et al. Increased trait-like impulsivity and course of illness in bipolar disorder. Bipolar Disord. 2009;11:280\u20138.","journal-title":"Bipolar Disord"},{"key":"449_CR55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-5618.2008.00657.x","volume":"11","author":"KM Holmes","year":"2009","unstructured":"Holmes KM, Bearden CE, Barguil M, et al. Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord. 2009;11:33\u201340.","journal-title":"Bipolar Disord"},{"key":"449_CR56","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1399-5618.2004.00110.x","volume":"6","author":"AC Swann","year":"2004","unstructured":"Swann AC, Dougherty DM, Pazzaglia PJ, et al. Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disord. 2004;6:204\u201312.","journal-title":"Bipolar Disord"},{"key":"449_CR57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1176\/appi.ajp.162.1.137","volume":"162","author":"E Hollander","year":"2005","unstructured":"Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137\u201345.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"449_CR58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0893-133X(01)00390-6","volume":"26","author":"AC Swann","year":"2002","unstructured":"Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26(4):530\u20136.","journal-title":"Neuropsychopharmacology."},{"key":"449_CR59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","volume":"108","author":"NC Maisel","year":"2013","unstructured":"Maisel NC, Blodgett JC, Wilbourne PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Meta-analysis of naltrexone and acamprosate. Addiction. 2013;108:275\u201393.","journal-title":"Addiction."},{"key":"449_CR60","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/JCP.0000000000000222","volume":"34","author":"BL Murphy","year":"2014","unstructured":"Murphy BL, Ravichandran C, Babb SM, Cohen BM. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34:749\u201351.","journal-title":"J Clin Psychopharmacol"},{"key":"449_CR61","first-page":"38","volume":"24","author":"S Beaulieu","year":"2012","unstructured":"Beaulieu S, Saury S, Sareen J, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry. 2012;24:38\u201355.","journal-title":"Ann Clin Psychiatry"},{"key":"449_CR62","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40263-015-0244-0","volume":"29","author":"R Guglielmo","year":"2015","unstructured":"Guglielmo R, Martinotti G, Quatrale M, et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29:383\u201395.","journal-title":"CNS Drugs"},{"key":"449_CR63","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38:1481\u20138.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4 Suppl","key":"449_CR64","first-page":"1","volume":"159","author":"American Psychiatric Association","year":"2002","unstructured":"American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1\u201350.","journal-title":"Am J Psychiatry"},{"key":"449_CR65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/foc.5.1.34","volume":"5","author":"RM Hirschfeld","year":"2007","unstructured":"Hirschfeld RM. Guideline watch (November 2005): practice guideline for the treatment of patients with bipolar disorder. Focus. 2007;5:34\u20139.","journal-title":"Focus."},{"key":"449_CR66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15622970801896390","volume":"9","author":"M Soyka","year":"2008","unstructured":"Soyka M, Kranzler HR, Berglund M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of substance use and related disorders, part 1: alcoholism. World J Biol Psychiatry. 2008;9:6\u201323.","journal-title":"World J Biol Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0449-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T00:25:49Z","timestamp":1569630349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0449-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0449-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]}}}